AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27990506 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform Switching (PS) group
Number of subjects: 18
Study 27990506 — intervention group
Group type: COMPARATOR
Intervention: Regular Platform (RP) group
Number of subjects: 18
Study 24356749 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide treatment for 48 weeks
Number of subjects: 747
Study 22104012 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus Deep Brain Stimulation (ODT + DBS)
Number of subjects: 30
Study 22104012 — intervention group
Group type: COMPARATOR
Intervention: Optimal Drug Therapy (ODT)
Number of subjects: 30
Study 20339970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (loading dose 0.5 microg/kg, maintenance dose 0.0075 microg/kg/min)
Number of subjects: 60
Study 20339970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 60
Study 20339970 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 60
Study 20339970 — intervention group
Group type: COMPARATOR
Intervention: Nesiritide and Nitroprusside
Number of subjects: 60
Study 18303248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid and transcranial color-coded duplex ultrasonography (CDUS)
Number of subjects: 19
Study 18303248 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 19
Study 15820796 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteally started triptorelin administration continued until the first day of hMG treatment (group S)
Number of subjects: 178
Study 15820796 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteally started triptorelin administration continued up to and including the fourth day of hMG treatment (group M)
Number of subjects: 178
Study 15820796 — intervention group
Group type: COMPARATOR
Intervention: Midluteally started triptorelin administration continued until the day of hCG injection (group L)
Number of subjects: 178
Study 14530749 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 45
Study 14530749 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous mixture)
Number of subjects: 45
Study 10737371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 10737371 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 0
Study 9275353 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise (Group I)
Number of subjects: 324
Study 9275353 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group II)
Number of subjects: 324
Study 1320740 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin-inactivated hepatitis A vaccine
Number of subjects: 1037
Study 1320740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1037
Study 6365465 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 55
Study 6365465 — intervention group
Group type: COMPARATOR
Intervention: Flupredniden acetate
Number of subjects: 55
Study 30825966 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 22
Study 30290717 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells (MSCs) from healthy donors, 90 million cells infused intravenously during high and very high activity disease flare-ups, followed by 9 months of follow-up.
Number of subjects: 3
Study 27593185 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEAL-CPMG
Number of subjects: 33
Study 27593185 — intervention group
Group type: COMPARATOR
Intervention: Dixon
Number of subjects: 33
Study 24224997 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT (targeted intraoperative radiotherapy)
Number of subjects: 3451
Study 24224997 — intervention group
Group type: COMPARATOR
Intervention: EBRT (whole-breast external beam radiotherapy)
Number of subjects: 3451
Study 24224997 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT (prepathology)
Number of subjects: 3451
Study 24224997 — intervention group
Group type: COMPARATOR
Intervention: EBRT (control for prepathology)
Number of subjects: 3451
Study 24224997 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT (postpathology)
Number of subjects: 3451
Study 24224997 — intervention group
Group type: COMPARATOR
Intervention: EBRT (control for postpathology)
Number of subjects: 3451
Study 24224997 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT
Number of subjects: 3451
Study 24224997 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 3451
Study 22738023 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing preoperatively and in the direct postoperative phase
Number of subjects: 120
Study 22738023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20333892 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding strategy task with remote eye-tracking device
Number of subjects: 0
Study 20333892 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanker task measuring resistance to interference
Number of subjects: 0
Study 20333892 — intervention group
Group type: EXPERIMENTAL
Intervention: Task measuring inhibition of attention to task-irrelevant stimuli (distractibility)
Number of subjects: 0
Study 20333892 — intervention group
Group type: COMPARATOR
Intervention: Basic aspects of attentional control
Number of subjects: 0
Study 17393526 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b)
Number of subjects: 245
Study 17393526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 17393526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined (IFN-gamma 1b and placebo)
Number of subjects: 245
Study 15871638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (0.25 g twice daily)
Number of subjects: 17
Study 15871638 — intervention group
Group type: COMPARATOR
Intervention: HAART alone (control)
Number of subjects: 17
Study 11953727 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (I‐NO) at doses of 5, 20, and 80 ppm
Number of subjects: 155
Study 11953727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 11953727 — intervention group
Group type: COMPARATOR
Intervention: Both I‐NO and placebo
Number of subjects: 155
Study 11153578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 microg daily for 3 months
Number of subjects: 36
Study 11153578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8819276 — intervention group
Group type: EXPERIMENTAL
Intervention: T tube drainage during bile duct reconstruction
Number of subjects: 60
Study 8819276 — intervention group
Group type: COMPARATOR
Intervention: No T tube drainage during bile duct reconstruction
Number of subjects: 60
Study 8819276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 1433876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 micrograms.kg‐1
Number of subjects: 32
Study 1433876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 32
Study 3893208 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural pethidine 50 mg
Number of subjects: 19
Study 3893208 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine 100 mg
Number of subjects: 19
Study 3893208 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 25 mg
Number of subjects: 19
Study 3893208 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural pethidine 50 mg and Epidural bupivacaine 25 mg
Number of subjects: 19
Study 3893208 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 19
Study 29787410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 29787410 — intervention group
Group type: COMPARATOR
Intervention: Nondexmedetomidine
Number of subjects: 80
Study 29782696 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus two ultrasounds and referral for complications
Number of subjects: 47423
Study 29782696 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (ANC)
Number of subjects: 47423
Study 26249150 — intervention group
Group type: EXPERIMENTAL
Intervention: mechano-chemical ablation +2% Polidocanol liquid
Number of subjects: 87
Study 26249150 — intervention group
Group type: EXPERIMENTAL
Intervention: mechano-chemical ablation +3% Polidocanol liquid
Number of subjects: 87
Study 26249150 — intervention group
Group type: EXPERIMENTAL
Intervention: mechano-chemical ablation +1% Polidocanol microfoam
Number of subjects: 87
Study 25207547 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablet (ambroxol 30 mg)
Number of subjects: 24
Study 25207547 — intervention group
Group type: EXPERIMENTAL
Intervention: Test capsule (ambroxol 30 mg)
Number of subjects: 24
Study 25207547 — intervention group
Group type: COMPARATOR
Intervention: Reference product (ambroxol 30 mg)
Number of subjects: 24
Study 24617028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (monthly consultations with primary care physician, weekly nutrition counseling for first 3 months, then monthly, and 12 group sessions in behavioral change protocol)
Number of subjects: 42
Study 24617028 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly consultations with primary care physician)
Number of subjects: 42
Study 24617028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 42
Study 24617028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 19512945 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-guided nursing intervention delivered by home health nurses via telephone
Number of subjects: 0
Study 19512945 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18052950 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 25 mg per day
Number of subjects: 14
Study 18052950 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg per day
Number of subjects: 14
Study 16214437 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion (25% glucose, 50 IU of soluble insulin per liter, and 80 mmol of potassium chloride per liter at 1 ml/kg/hour over 24 hours)
Number of subjects: 120
Study 16214437 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion
Number of subjects: 120
Study 12404671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (180 mg/day)
Number of subjects: 262
Study 12404671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 10096258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 12
Study 10096258 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg twice a day)
Number of subjects: 12
Study 10096258 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 12
Study 7780277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole eye drops
Number of subjects: 30
Study 7780277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2086421 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified O'Brien block
Number of subjects: 32
Study 2086421 — intervention group
Group type: COMPARATOR
Intervention: Modified van Lint block
Number of subjects: 32
Study 2086421 — intervention group
Group type: COMPARATOR
Intervention: Atkinson block
Number of subjects: 32
Study 29271282 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Workstation condition (n = 35)
Number of subjects: 71
Study 29271282 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 36)
Number of subjects: 71
Study 28557022 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted cluster-level analysis
Number of subjects: 0
Study 28557022 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline covariate-adjusted cluster-level analysis
Number of subjects: 0
Study 28557022 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects logistic regression
Number of subjects: 0
Study 28557022 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised estimating equations
Number of subjects: 0
Study 28557022 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete records analysis
Number of subjects: 0
Study 28557022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel multiple imputation
Number of subjects: 0
Study 26323511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Haloperidol
Number of subjects: 10
Study 26323511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Midazolam
Number of subjects: 10
Study 23721797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program with knee stabilization training
Number of subjects: 159
Study 23721797 — intervention group
Group type: COMPARATOR
Intervention: Exercise program focusing on muscle strength and daily activities only (Control)
Number of subjects: 159
Study 21784190 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (0.75 μg daily)
Number of subjects: 1054
Study 19254604 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity, shorter duration (MISD) exercise
Number of subjects: 55
Study 19254604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, longer duration (LILD) exercise
Number of subjects: 55
Study 19254604 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic exercise (TE)
Number of subjects: 55
Study 16707748 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 2006
Study 16707748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study 14996859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy with chemotherapy
Number of subjects: 558
Study 14996859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy without chemotherapy
Number of subjects: 558
Study 14996859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy with chemotherapy
Number of subjects: 558
Study 14996859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy without chemotherapy
Number of subjects: 558
Study 14996859 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 558
Study 14996859 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 558
Study 14996859 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 558
Study 11318765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg i.v.)
Number of subjects: 12
Study 11318765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9455272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose-based fibre dressing
Number of subjects: 40
Study 9455272 — intervention group
Group type: COMPARATOR
Intervention: Ribbon gauze
Number of subjects: 40
Study 7934351 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1011
Study 7934351 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1011
Study 3360055 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (controlled-release formulation)
Number of subjects: 8
Study 3360055 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (conventional formulation)
Number of subjects: 8
Study 3360055 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 8
Study 3360055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29154689 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive vagal nerve stimulation
Number of subjects: 10
Study 29154689 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 27522346 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Only (PO)
Number of subjects: 30
Study 27522346 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Observation (SO)
Number of subjects: 30
Study 27522346 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Observation (EO)
Number of subjects: 30
Study 27522346 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 25896965 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg mifepristone followed by 400 μg buccal misoprostol every 3 hours until complete fetal and placental expulsion (maximum 10 doses)
Number of subjects: 120
Study 25896965 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by 400 μg buccal misoprostol every 3 hours until complete fetal and placental expulsion (maximum 10 doses)
Number of subjects: 120
Study 25896965 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg mifepristone followed by 400 μg buccal misoprostol
Number of subjects: 120
Study 25896965 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by 400 μg buccal misoprostol
Number of subjects: 120
Study 23668248 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer instruction
Number of subjects: 0
Study 23668248 — intervention group
Group type: COMPARATOR
Intervention: Faculty instruction
Number of subjects: 0
Study 20684442 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible dental decay (central position of caries)
Number of subjects: 100
Study 20684442 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible dental decay (presence of decay)
Number of subjects: 100
Study 20684442 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible dental decay (twice the amount of decay)
Number of subjects: 100
Study 20684442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visible decay)
Number of subjects: 100
Study 19052336 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated nets (lambdacyhalothrin 2.5 CS at 10 mg (a.i.)/m(2))
Number of subjects: 1500
Study 19052336 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated nets
Number of subjects: 1500
Study 19052336 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated nets
Number of subjects: 1500
Study 16466494 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach 1 (specified adverse effects) + floating subheadings + text words for 'adverse effects' in MEDLINE
Number of subjects: 0
Study 16466494 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach 1 (specified adverse effects) + text words for 'adverse effects' in EMBASE
Number of subjects: 0
Study 14610432 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced education group (EEG)
Number of subjects: 25
Study 14610432 — intervention group
Group type: COMPARATOR
Intervention: Conventional education group (CEG)
Number of subjects: 25
Study 11075307 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cyclosporin A (ADI628) 10 mg single dose
Number of subjects: 0
Study 11075307 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cyclosporin A (ADI628) 20 mg dose group
Number of subjects: 0
Study 11075307 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cyclosporin A (ADI628) 10 mg bid (highest steady-state dose)
Number of subjects: 0
Study 11075307 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated inhaled doses of ADI628
Number of subjects: 0
Study 11075307 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclosporin A (3 mg/kg)
Number of subjects: 0
Study 9025127 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD-CPR
Number of subjects: 152
Study 9025127 — intervention group
Group type: COMPARATOR
Intervention: STD-CPR
Number of subjects: 152
Study 1679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol MDI (50 micrograms)
Number of subjects: 12
Study 1679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol DPI (50 micrograms)
Number of subjects: 12
Study 1679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 12
Study 1679981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol MDI and DPI
Number of subjects: 12
Study 1679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol MDI (2.21 mumol)
Number of subjects: 12
Study 1679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol DPI (1.88 mumol)
Number of subjects: 12
Study 6839003 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobid (260 mg)
Number of subjects: 9
Study 6839003 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur (200 mg)
Number of subjects: 9
Study 6839003 — intervention group
Group type: EXPERIMENTAL
Intervention: Choledyl (128 mg)
Number of subjects: 9
Study 31635890 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole oral suspension 50 mg/10 mL via nasogastric tube
Number of subjects: 32
Study 31635890 — intervention group
Group type: COMPARATOR
Intervention: Riluzole oral suspension 50 mg/10 mL orally
Number of subjects: 32
Study 30630793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of methotrexate and immune adsorption
Number of subjects: 56
Study 30630793 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 56
Study 26511959 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (total dose 60 mg/kg given as two split doses)
Number of subjects: 370
Study 26511959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 26511959 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 370
Study 24858669 — intervention group
Group type: EXPERIMENTAL
Intervention: M Technique intervention (7‐minute session, 6 times per week for 5 weeks)
Number of subjects: 20
Study 24858669 — intervention group
Group type: EXPERIMENTAL
Intervention: M Technique intervention
Number of subjects: 20
Study 24858669 — intervention group
Group type: COMPARATOR
Intervention: Standard NICU care
Number of subjects: 20
Study 22597706 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard admission orders
Number of subjects: 5338
Study 22597706 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite process-of-care measure
Number of subjects: 5338
Study 20488274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 563
Study 20488274 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 563
Study 20488274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (dietary counseling and control)
Number of subjects: 563